Laura E.Koman

Associate

Washington + 1.202.879.3601

Laura Koman advises health care and life sciences companies on transactional and regulatory matters, with a particular emphasis on digital health.

Laura has advised hospitals, health systems, provider groups, and established and emerging companies concerning e-health topics such as direct-to-consumer telemedicine, provider-to-provider consults, e-prescribing, licensure, remote supervision, reimbursement, patient consent, and corporate structure and corporate practice of medicine issues. She also has participated in structuring various health care transactions, including health care acquisitions, joint ventures, management service agreements, and other arrangements for the provision of professional, practice management, or administrative services. Laura's experience includes counseling clients on health care fraud and abuse issues, including compliance with the Stark Law and Anti-Kickback Statute.

On the life sciences side, Laura advises clients on issues surrounding the regulation of drug, medical device, food, dietary supplement, and cosmetic products by the FDA, CPSC, and other federal and state agencies and provides support to clients engaged in life sciences M&A and other transactions, including due diligence.

Laura maintains an active pro bono practice that includes providing advice to nonprofit organizations relating to governance and formation and volunteering with the D.C. Bar Association's Landlord Tenant Resource Center. She also recently represented an individual seeking social security disability benefits as a volunteer for the Washington Legal Clinical for the Homeless.

Laura is a member of the American Health Lawyers Association.

Experience

  • Riverside sells ActivStyle to AdaptHealthJones Day is advising The Riverside Company in its sale of ActivStyle, a distributor of consumable medical supplies with an emphasis on incontinence products, to AdaptHealth Corp.
  • Telehealth company expands programming in response to COVID-19 public health crisisJones Day represented a telehealth company in the expansion of their telehealth programming in response to the COVID-19 public health crisis and related health regulatory and contracting matters.
  • Large critical infrastructure employer considers implementing COVID-19 testing program for employeesJones Day represented a large critical infrastructure employer during the COVID-19 crisis to consider and assess appropriate protocols and policies for implementing an employee COVID-19 testing program at its sites. This included counseling on myriad federal, state, and local legal and regulatory frameworks as well as forming appropriate partnerships.
  • Large critical infrastructure employer develops and implements protocol for international relocation of essential workers during COVID-19 pandemicJones Day represented a large critical infrastructure employer during the COVID-19 crisis to develop appropriate protocols and policies for the international relocation of several employees in accordance with CDC guidelines.
  • National digital health company launches government partnershipJones Day advised a large digital health company with multi-clinical services in negotiating a partnership with a state government program to provide telehealth and telemedicine consults during the COVID-19 state of emergency.
  • Smith & Nephew acquires Tusker Medical, Inc.Jones Day advised Smith & Nephew plc, the global medical technology company, in the acquisition of Tusker Medical, Inc., the developer of the Tula System, an in-office solution for tympanostomy tubes (commonly known as ear tubes).
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Misonix acquires Solsys Medical, LLC for $109 millionJones Day advised Misonix, Inc. in its acquisition of Solsys Medical, LLC, a privately held regenerative medical company, in an all-stock transaction valued at approximately $109 million.
  • Large multi-state corporation reviews compliance with state corporate practice of medicine laws and regulationsJones Day advised a private multi-state corporation on compliance with corporate practice of medicine laws and regulations in multiple states with respect to the corporation's employed health care practitioners providing clinical services to the corporation's employees.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
  • Riverside acquires Champion Healthcare TechnologiesJones Day represented The Riverside Company in connection with the acquisition and related financings of Champion Healthcare Technologies, a SaaS provider that enables hospitals to manage surgical implants throughout their life cycle.
  • Large health system advised on regulatory and reimbursement matters for telehealth and telemedicine activitiesJones Day is providing ongoing advice to a large hospital/health system related to telehealth and telemedicine reimbursement and regulatory matters.
  • Curavi acquires TripleCareJones Day advised University of Pittsburgh Medical Center ("UPMC) and Curavi, in the acquisition by subsidiary Curavi of TripleCare, a Long Island City, New York-based provider of telemedicine solutions for the post-acute, long-term care industry, including skilled nursing facilities.
  • Dietary supplement manufacturer obtains withdrawal of threatened class action alleging false label claimsJones Day represented a dietary supplement manufacturer who received a draft class action complaint alleging that the manufacturer's products falsely claimed non-existent health benefits.
  • WMATA engages advisors for executive boardJones Day is serving as the strategic executive advisor to the Washington Metropolitan Area Transit Authority's General Manager/Chief Executive Officer and its Board of Directors in connection with its efforts to evaluate its finances, operations, and governance.
  • Emerging digital health company launches multi-state telehealth platformJones Day advised an emerging digital health company in launching its telehealth operations in multiple states throughout the U.S., with additional expansion to come.
  • Large digital health company grows operations across U.S.Jones Day advised a large digital health company in expanding operations throughout multiple states in the U.S. and in responding to several state regulator inquiries regarding its operations.
  • Koch Disruptive Technologies leads $150 million investment in INSIGHTECJones Day advised Koch Disruptive Technologies, a subsidiary of Koch Industries, Inc. focused on finding and funding innovative and emerging companies, as the lead investor in a $150 million Series E funding round for INSIGHTEC, a commercial stage medical device company.
  • Smith & Nephew acquires Rotation Medical Inc. for up to $210 millionJones Day advised Smith & Nephew plc in its acquisition of Rotation Medical Inc., a developer of a novel tissue regeneration technology for shoulder rotator cuff repair, for an initial cash consideration of $125 million and up to $85 million over the next five years, contingent on financial performance.
  • Speaking Engagements

    • August 1, 2019
      11th Annual mHealth and Telehealth World Summit―Addressing the Legal and Regulatory Barriers to Expand Telehealth Capabilities
    • April 14, 2019
      ATA19—Direct-to-Consumer Telemedicine – Lessons Learned and Strategies for Advancing Policy
    • March 22, 2019
      Institute on Medicare and Medicaid Payment Issues—2019 Changes to Medicare Reimbursement for Telehealth and Communication Technology Based Services
    • October 10, 2018
      AHLA Telemedicine Webinar Series—Part I: Fundamentals of Telemedicine Legal and Regulatory
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.